258 related articles for article (PubMed ID: 27738818)
1. Embolotherapy for Neuroendocrine Tumor Liver Metastases: Prognostic Factors for Hepatic Progression-Free Survival and Overall Survival.
Chen JX; Rose S; White SB; El-Haddad G; Fidelman N; Yarmohammadi H; Hwang W; Sze DY; Kothary N; Stashek K; Wileyto EP; Salem R; Metz DC; Soulen MC
Cardiovasc Intervent Radiol; 2017 Jan; 40(1):69-80. PubMed ID: 27738818
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of baseline volumetric multiparametric MR imaging in neuroendocrine liver metastases treated with transarterial chemoembolization.
Luo Y; Pandey A; Ghasabeh MA; Pandey P; Varzaneh FN; Zarghampour M; Khoshpouri P; Ameli S; Li Z; Hu D; Kamel IR
Eur Radiol; 2019 Oct; 29(10):5160-5171. PubMed ID: 30877462
[TBL] [Abstract][Full Text] [Related]
3. Transarterial Chemoembolization vs Radioembolization for Neuroendocrine Liver Metastases: A Multi-Institutional Analysis.
Egger ME; Armstrong E; Martin RC; Scoggins CR; Philips P; Shah M; Konda B; Dillhoff M; Pawlik TM; Cloyd JM
J Am Coll Surg; 2020 Apr; 230(4):363-370. PubMed ID: 32032719
[TBL] [Abstract][Full Text] [Related]
4. Survival outcomes and prognostic factors of transcatheter arterial chemoembolization for hepatic neuroendocrine metastases.
Hur S; Chung JW; Kim HC; Oh DY; Lee SH; Bang YJ; Kim WH
J Vasc Interv Radiol; 2013 Jul; 24(7):947-56; quiz 957. PubMed ID: 23602421
[TBL] [Abstract][Full Text] [Related]
5. Neuroendocrine liver metastases treated using transarterial radioembolization: Identification of prognostic parameters at 68Ga-DOTATATE PET/CT.
Ingenerf M; Grawe F; Winkelmann M; Karim H; Ruebenthaler J; Fabritius MP; Ricke J; Seidensticker R; Auernhammer CJ; Zacherl MJ; Seidensticker M; Schmid-Tannwald C
Diagn Interv Imaging; 2024 Jan; 105(1):15-25. PubMed ID: 37453859
[TBL] [Abstract][Full Text] [Related]
6. Transarterial embolization (TAE) is equally effective and slightly safer than transarterial chemoembolization (TACE) to manage liver metastases in neuroendocrine tumors.
Fiore F; Del Prete M; Franco R; Marotta V; Ramundo V; Marciello F; Di Sarno A; Carratù AC; de Luca di Roseto C; Colao A; Faggiano A
Endocrine; 2014 Sep; 47(1):177-82. PubMed ID: 24385266
[TBL] [Abstract][Full Text] [Related]
7. Randomized Embolization Trial for NeuroEndocrine Tumor Metastases to the Liver (RETNET): study protocol for a randomized controlled trial.
Chen JX; Wileyto EP; Soulen MC
Trials; 2018 Jul; 19(1):390. PubMed ID: 30016989
[TBL] [Abstract][Full Text] [Related]
8. DAXX Mutation Status of Embolization-Treated Neuroendocrine Tumors Predicts Shorter Time to Hepatic Progression.
Ziv E; Rice SL; Filtes J; Yarmohammadi H; Boas FE; Erinjeri JP; Petre EN; Brody LA; Brown KT; Covey AM; Getrajdman GI; Maybody M; Raj N; Sofocleous CT; Solomon SB; Reidy-Lagunes D
J Vasc Interv Radiol; 2018 Nov; 29(11):1519-1526. PubMed ID: 30342802
[TBL] [Abstract][Full Text] [Related]
9. Semi-quantitative visual assessment of hepatic tumor burden can reliably predict survival in neuroendocrine liver metastases treated with transarterial chemoembolization.
Luo Y; Ameli S; Pandey A; Khoshpouri P; Ghasabeh MA; Pandey P; Li Z; Hu D; Kamel IR
Eur Radiol; 2019 Nov; 29(11):5804-5812. PubMed ID: 31073860
[TBL] [Abstract][Full Text] [Related]
10. Hepatic artery embolization in advanced neuroendocrine tumors: Efficacy and long-term outcomes.
Pericleous M; Caplin ME; Tsochatzis E; Yu D; Morgan-Rowe L; Toumpanakis C
Asia Pac J Clin Oncol; 2016 Mar; 12(1):61-9. PubMed ID: 26663886
[TBL] [Abstract][Full Text] [Related]
11. Intra-arterial therapy of neuroendocrine tumour liver metastases: comparing conventional TACE, drug-eluting beads TACE and yttrium-90 radioembolisation as treatment options using a propensity score analysis model.
Do Minh D; Chapiro J; Gorodetski B; Huang Q; Liu C; Smolka S; Savic LJ; Wainstejn D; Lin M; Schlachter T; Gebauer B; Geschwind JF
Eur Radiol; 2017 Dec; 27(12):4995-5005. PubMed ID: 28677067
[TBL] [Abstract][Full Text] [Related]
12. Hepatic intra-arterial therapies in metastatic neuroendocrine tumors: lessons from clinical practice.
Grozinsky-Glasberg S; Kaltsas G; Kaltsatou M; Lev-Cohain N; Klimov A; Vergadis V; Uri I; Bloom AI; Gross DJ
Endocrine; 2018 Jun; 60(3):499-509. PubMed ID: 29383678
[TBL] [Abstract][Full Text] [Related]
13. Hepatic arterial embolization and chemoembolization for imatinib-resistant gastrointestinal stromal tumors.
Kobayashi K; Szklaruk J; Trent JC; Ensor J; Ahrar K; Wallace MJ; Madoff DC; Murthy R; Hicks ME; Gupta S
Am J Clin Oncol; 2009 Dec; 32(6):574-81. PubMed ID: 19636238
[TBL] [Abstract][Full Text] [Related]
14. Elevated Alkaline Phosphatase Prior to Transarterial Chemoembolization for Neuroendocrine Tumors Predicts Worse Outcomes.
Onesti JK; Shirley LA; Saunders ND; Davidson GW; Dillhoff ME; Khabiri H; Guy GE; Dowell JD; Schmidt CR; Shah MH; Bloomston M
J Gastrointest Surg; 2016 Mar; 20(3):580-6. PubMed ID: 26489743
[TBL] [Abstract][Full Text] [Related]
15. Neutrophil Lymphocyte Ratio and Transarterial Chemoembolization in Neuroendocrine Tumor Metastases.
McDermott SM; Saunders ND; Schneider EB; Strosberg D; Onesti J; Dillhoff M; Schmidt CR; Shirley LA
J Surg Res; 2018 Dec; 232():369-375. PubMed ID: 30463743
[TBL] [Abstract][Full Text] [Related]
16. Comparison of transarterial bland and chemoembolization for neuroendocrine tumours: a systematic review and meta-analysis.
Tai E; Kennedy S; Farrell A; Jaberi A; Kachura J; Beecroft R
Curr Oncol; 2020 Dec; 27(6):e537-e546. PubMed ID: 33380868
[TBL] [Abstract][Full Text] [Related]
17. Liver-dominant Breast Cancer Metastasis: A Comparative Outcomes Study of Chemoembolization
Chang J; Charalel R; Noda C; Ramaswamy R; Kim SK; Darcy M; Foltz G; Akinwande O
Anticancer Res; 2018 May; 38(5):3063-3068. PubMed ID: 29715141
[TBL] [Abstract][Full Text] [Related]
18. Combined Effects of Yttrium-90 Transarterial Radioembolization around Immunotherapy for Hepatic Metastases from Uveal Melanoma: A Preliminary Retrospective Case Series.
Zheng J; Irani Z; Lawrence D; Flaherty K; Arellano RS
J Vasc Interv Radiol; 2018 Oct; 29(10):1369-1375. PubMed ID: 30174161
[TBL] [Abstract][Full Text] [Related]
19. Role of hepatic intra-arterial therapies in metastatic neuroendocrine tumours (NET): guidelines from the NET-Liver-Metastases Consensus Conference.
Kennedy A; Bester L; Salem R; Sharma RA; Parks RW; Ruszniewski P;
HPB (Oxford); 2015 Jan; 17(1):29-37. PubMed ID: 25186181
[TBL] [Abstract][Full Text] [Related]
20. Outcomes After Transarterial Embolization of Neuroendocrine Tumor Liver Metastases Using Spherical Particles of Different Sizes.
Zener R; Yoon H; Ziv E; Covey A; Brown KT; Sofocleous CT; Thornton RH; Boas FE
Cardiovasc Intervent Radiol; 2019 Apr; 42(4):569-576. PubMed ID: 30627774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
